Fairfield, Bush & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

Fairfield, Bush & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12	Closed	-$2K	–	284
2022 Q2	$2K	Buy	+12	New	+$1.85K	﹤0.01%	394

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fairfield, Bush & Co's JAZZ Position: Q3 2022 in Review

Fairfield, Bush & Co sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2022, closing a stake of 12 shares — an estimated $2K sold.

Fairfield, Bush & Co first reported a position in JAZZ in Q2 2022 and held it in 1 quarter. The position peaked at $2K in Q2 2022. 468 funds tracked by Wall St. Rank hold JAZZ as of Q3 2022.

Fairfield, Bush & Co reported no remaining Jazz Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Fairfield, Bush & Co sold 12 Jazz Pharmaceuticals shares in Q3 2022, an estimated $2K.
Fairfield, Bush & Co first reported a position in Jazz Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Fairfield, Bush & Co's Jazz Pharmaceuticals position peaked at $2K in Q2 2022.
468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2022.

Based on Fairfield, Bush & Co's 13F filing for Q3 2022, filed 7 Nov 2022.